Summary
SM-5887, a new totally synthetic anthracycline derivative was studied in a phase I setting. Twenty-nine evaluable courses of treatment were conducted in groups at doses increasing from 10 to 130 mg/m2. Myelosuppression was the dose-limiting toxicity and a MTD was 130 mg/m2. At 130 mg/m2 the median lowest white blood cell count was 0.7 × 103/cmm (range: 0.3–1.8) and the median lowest granulocyte count was 0.1 × 103/cmm (range: 0–0.7) and the median lowest platelet count was 57 × l03/cmm (range: 4–176). Nonhematologic side effects were mild gastrointestinal symptoms and hair loss. The recommended dose and schedule for phase II setting is 100 mg/m2 every 3 weeks.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ishigami K, Ohashi N, Tanno N: Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J Organic Chemistry 52:4477–4485, 1987
Kashiwazaki Y, Morisada S, Fukui M, et al.: Antitumor activity of a novel anthracycline, SM-5887. (Abstr) Proc of the Japanese Cancer Association, Tokyo, 1985, p. 259
Suzuki T, Arai M, Iwasaki T, Yamamoto H, Kanda H: The cardiotoxicity of a new anthracycline, SM-5887, in rabbits. (Abstr) Proc of the Japanese Cancer Association, Tokyo, p 447, 1987
Yamaoka K, Tanigawara Y, Nakagawa T, et al.: A pharmacokinetics analysis program (MULTI) for microcomputer. J Pharm Dyn 4:879–885, 1981
Benjamin RS, Riggs CE, Bachur NR: Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther 14:592–600, 1973
DiFronzo G, Lenaz L, Bonadonna G: Distribution and excretion of adriamycin in man. Biomedicine 19:169–171, 1973
Nakajima O, Imamura Y, Matsumoto A, Koyama Y, Shomura T, Kawamura K, Murata S: Comparative studies on pharmacokinetics between THP and adriamycin in the same patients. Jpn J Cancer Chemother 13(2):261–270, 1986
Mizuno Y, Kimura K, Yoshitake A: Disposition of SM-5887, new anthracycline anti-tumor agents, in rat. (Abstr) Proc of the Japanese Cancer Association, Tokyo, p 442, 1987